The specter of generic competition has consistently loomed above copyright’s blockbuster drug, Viagra, triggering questions Pharma about the prospects of related drug investments. While first times saw significant returns, the exclusivity end has opened the way for cheaper alternatives, possibly reducing earnings and posing a significant risk for